Cynosure (CYNO) Reaches New Lifetime High Today
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Cynosure as such a stock due to the following factors:
- CYNO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $12.1 million.
- CYNO has traded 10,169 shares today.
- CYNO is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in CYNO with the Ticky from Trade-Ideas. See the FREE profile for CYNO NOW at Trade-Ideas
More details on CYNO:
Cynosure, Inc. develops, manufactures, and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners. CYNO has a PE ratio of 63. Currently there are 7 analysts that rate Cynosure a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Cynosure has been 366,600 shares per day over the past 30 days. Cynosure has a market cap of $1.2 billion and is part of the health care sector and health services industry. The stock has a beta of 1.66 and a short float of 6.3% with 6.66 days to cover. Shares are up 16.7% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Cynosure as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 5.7%. Since the same quarter one year prior, revenues rose by 26.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
- CYNO's debt-to-equity ratio is very low at 0.04 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, CYNO has a quick ratio of 1.93, which demonstrates the ability of the company to cover short-term liquidity needs.
- This stock has managed to rise its share value by 24.04% over the past twelve months. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 35687.5% when compared to the same quarter one year prior, rising from -$0.01 million to $2.85 million.
- Net operating cash flow has significantly increased by 92.72% to -$0.35 million when compared to the same quarter last year. In addition, CYNOSURE INC has also vastly surpassed the industry average cash flow growth rate of -17.43%.
- You can view the full Cynosure Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.